Other formats:
BibTeX
LaTeX
RIS
@article{1834649,
author = {Kopecky, Jindrich and Kubecek, Ondrej and Buchler, Tomas and Melichar, Bohuslav and Poprach, Alexandr and Zemanova, Milada and Katolicka, Jana and Kiss, Igor and Hajek, Jaroslav and Studentova, Hana and Spisarova, Martina},
article_location = {ATHENS},
article_number = {5},
doi = {http://dx.doi.org/10.21873/invivo.12593},
keywords = {Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index},
language = {eng},
issn = {0258-851X},
journal = {In vivo},
title = {Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors},
url = {https://iv.iiarjournals.org/content/35/5/2981},
volume = {35},
year = {2021}
}
TY - JOUR
ID - 1834649
AU - Kopecky, Jindrich - Kubecek, Ondrej - Buchler, Tomas - Melichar, Bohuslav - Poprach, Alexandr - Zemanova, Milada - Katolicka, Jana - Kiss, Igor - Hajek, Jaroslav - Studentova, Hana - Spisarova, Martina
PY - 2021
TI - Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
JF - In vivo
VL - 35
IS - 5
SP - 2981-2990
EP - 2981-2990
PB - Greece : International Institute of Anticancer Research
SN - 0258851X
KW - Renal cell cancer
KW - nivolumab
KW - mTOR inhibitor
KW - neutrophil-lymphocyte ratio
KW - platelet-lymphocyte ratio
KW - systematic inflammation index
UR - https://iv.iiarjournals.org/content/35/5/2981
N2 - Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
ER -
KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH, Milada ZEMANOVA, Jana KATOLICKA, Igor KISS, Jaroslav HAJEK, Hana STUDENTOVA and Martina SPISAROVA. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol.~35, No~5, p.~2981-2990. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12593.
|
